Tempus AI Director Sells Stock Before Significant Rally
Nadja West, a director at Tempus AI (TEM), sold 3,000 shares of Class A Common Stock on August 14 for $53.90 per share under a pre-established Rule 10b5-1 trading plan set up in May. The transaction occurred four days before the stock surged by over 24%, potentially linked to positive news about Moderna and Merck's cancer vaccine trial results. Tempus AI, based in Chicago, operates a healthcare technology platform focused on integrating clinical diagnostics with physician workflows through next-generation sequencing tests and analytics. Despite generating $1.4 billion in trailing twelve-month revenue, the company reported a net loss of $254.4 million for the same period. The sale represents a relatively small portion of West's holdings—she still owns 34,981 shares directly—and is not seen as indicative of negative sentiment toward the stock or its future prospects.
Topics: director activity SEC filing stock sale